Form 4: Tarsus Pharmaceuticals CFO Jeffrey Farrow Reports Stock Option and Restricted Stock Unit Grants

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• Jeffrey Farrow, the Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, reported changes in his beneficial ownership of the company's securities.
• On March 7, 2024, Farrow acquired stock options for 47,500 shares with an exercise price of $35.50, vesting over four years.
• He also acquired 32,079 restricted stock units (RSUs), each representing a contingent right to receive one share of Tarsus Pharmaceuticals' common stock, vesting annually over four years starting March 15, 2025.
• Following these transactions, Farrow directly owns 47,500 stock options and 32,079 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it is a routine disclosure of stock options and RSU grants to an executive. It's a standard practice and doesn't necessarily indicate positive or negative performance.

Positives

• The grant of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment and performance.

Industry Context

Stock option and RSU grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are common in the pharmaceutical industry.
• Companies like Alcon and Bausch + Lomb also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules are fairly standard, aligning with industry norms for retaining key personnel.

Stakeholder Impact

• The grants incentivize the CFO to work towards increasing shareholder value.
• Employees may be indirectly impacted by the CFO's performance.

Key Dates